124 related articles for article (PubMed ID: 29976737)
1. Idelalisib impairs T-cell-mediated immunity in chronic lymphocytic leukemia.
Martinelli S; Maffei R; Fiorcari S; Quadrelli C; Zucchini P; Benatti S; Potenza L; Luppi M; Marasca R
Haematologica; 2018 Dec; 103(12):e598-e601. PubMed ID: 29976737
[No Abstract] [Full Text] [Related]
2. Idelalisib and bendamustine combination is synergistic and increases DNA damage response in chronic lymphocytic leukemia cells.
Modi P; Balakrishnan K; Yang Q; Wierda WG; Keating MJ; Gandhi V
Oncotarget; 2017 Mar; 8(10):16259-16274. PubMed ID: 28187444
[TBL] [Abstract][Full Text] [Related]
3. The PI3K∂-Selective Inhibitor Idelalisib Induces T- and NK-Cell Dysfunction Independently of B-Cell Malignancy-Associated Immunosuppression.
Rohrbacher L; Brauchle B; Ogrinc Wagner A; von Bergwelt-Baildon M; Bücklein VL; Subklewe M
Front Immunol; 2021; 12():608625. PubMed ID: 33790890
[TBL] [Abstract][Full Text] [Related]
4. Idelalisib for optimized CD19-specific chimeric antigen receptor T cells in chronic lymphocytic leukemia patients.
Stock S; Übelhart R; Schubert ML; Fan F; He B; Hoffmann JM; Wang L; Wang S; Gong W; Neuber B; Hückelhoven-Krauss A; Gern U; Christ C; Hexel M; Schmitt A; Schmidt P; Krauss J; Jäger D; Müller-Tidow C; Dreger P; Schmitt M; Sellner L
Int J Cancer; 2019 Sep; 145(5):1312-1324. PubMed ID: 30737788
[TBL] [Abstract][Full Text] [Related]
5. Idelalisib and caffeine reduce suppression of T cell responses mediated by activated chronic lymphocytic leukemia cells.
Hock BD; MacPherson SA; McKenzie JL
PLoS One; 2017; 12(3):e0172858. PubMed ID: 28257435
[TBL] [Abstract][Full Text] [Related]
6. Chemotherapy-induced augmentation of T cells expressing inhibitory receptors is reversed by treatment with lenalidomide in chronic lymphocytic leukemia.
Gassner FJ; Zaborsky N; Neureiter D; Huemer M; Melchardt T; Egle A; Rebhandl S; Catakovic K; Hartmann TN; Greil R; Geisberger R
Haematologica; 2014 May; 99(5):67-9. PubMed ID: 24561794
[No Abstract] [Full Text] [Related]
7. Efficacy of phosphatidylinositol-3 kinase inhibitors with diverse isoform selectivity profiles for inhibiting the survival of chronic lymphocytic leukemia cells.
Göckeritz E; Kerwien S; Baumann M; Wigger M; Vondey V; Neumann L; Landwehr T; Wendtner CM; Klein C; Liu N; Hallek M; Frenzel LP; Krause G
Int J Cancer; 2015 Nov; 137(9):2234-42. PubMed ID: 25912635
[TBL] [Abstract][Full Text] [Related]
8. Idelalisib for the treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma.
Barrientos JC
Future Oncol; 2016 Sep; 12(18):2077-94. PubMed ID: 27324214
[TBL] [Abstract][Full Text] [Related]
9. Idelalisib.
Zirlik K; Veelken H
Recent Results Cancer Res; 2018; 212():243-264. PubMed ID: 30069634
[TBL] [Abstract][Full Text] [Related]
10. PI3Kδ inhibition modulates regulatory and effector T-cell differentiation and function in chronic lymphocytic leukemia.
Hanna BS; Roessner PM; Scheffold A; Jebaraj BMC; Demerdash Y; Öztürk S; Lichter P; Stilgenbauer S; Seiffert M
Leukemia; 2019 Jun; 33(6):1427-1438. PubMed ID: 30573773
[TBL] [Abstract][Full Text] [Related]
11. Idelalisib Rescues Natural Killer Cells from Monocyte-Induced Immunosuppression by Inhibiting NOX2-Derived Reactive Oxygen Species.
Akhiani AA; Hallner A; Kiffin R; Aydin E; Werlenius O; Aurelius J; Martner A; Thorén FB; Hellstrand K
Cancer Immunol Res; 2020 Dec; 8(12):1532-1541. PubMed ID: 32967913
[TBL] [Abstract][Full Text] [Related]
12. Bone marrow stroma-induced resistance of chronic lymphocytic leukemia cells to arsenic trioxide involves Mcl-1 upregulation and is overcome by inhibiting the PI3Kδ or PKCβ signaling pathways.
Amigo-Jiménez I; Bailón E; Aguilera-Montilla N; Terol MJ; García-Marco JA; García-Pardo A
Oncotarget; 2015 Dec; 6(42):44832-48. PubMed ID: 26540567
[TBL] [Abstract][Full Text] [Related]
13. Epigenetic repolarization of T lymphocytes from chronic lymphocytic leukemia patients using 5-aza-2'-deoxycytidine.
Dubovsky JA; Powers JJ; Gao Y; Mariusso LF; Sotomayor EM; Pinilla-Ibarz JA
Leuk Res; 2011 Sep; 35(9):1193-9. PubMed ID: 21377729
[TBL] [Abstract][Full Text] [Related]
14. Idelalisib plus rituximab is effective in systemic AL amyloidosis secondary to chronic lymphocytic leukaemia.
Visentin A; Briani C; Imbergamo S; Frezzato F; Angelini A; Fedrigo M; Cacciavillani M; Altinier S; Piazza F; Semenzato G; Adami F; Trentin L
Hematol Oncol; 2018 Feb; 36(1):366-369. PubMed ID: 28971495
[TBL] [Abstract][Full Text] [Related]
15. Idelalisib improves CD37 antibody BI 836826 cytotoxicity against chemo-resistant /relapse-initiating CLL cells: a rationale for combination treatment.
Betrian S; Ysebaert L; Heider KH; Delord JP; Fournié JJ; Quillet-Mary A
Blood Cancer J; 2016 Nov; 6(11):e496. PubMed ID: 27834943
[No Abstract] [Full Text] [Related]
16. Idelalisib induces G1 arrest and apoptosis in chronic myeloid leukemia K562 cells.
Chen Y; Zhou Q; Zhang L; Wang R; Jin M; Qiu Y; Kong D
Oncol Rep; 2016 Dec; 36(6):3643-3650. PubMed ID: 27748929
[TBL] [Abstract][Full Text] [Related]
17. Idelalisib induces PUMA-dependent apoptosis in colon cancer cells.
Yang S; Zhu Z; Zhang X; Zhang N; Yao Z
Oncotarget; 2017 Jan; 8(4):6102-6113. PubMed ID: 28008149
[TBL] [Abstract][Full Text] [Related]
18. Distinct roles for phosphoinositide 3-kinases γ and δ in malignant B cell migration.
Ali AY; Wu X; Eissa N; Hou S; Ghia JE; Murooka TT; Banerji V; Johnston JB; Lin F; Gibson SB; Marshall AJ
Leukemia; 2018 Sep; 32(9):1958-1969. PubMed ID: 29479062
[TBL] [Abstract][Full Text] [Related]
19. The pan phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor SAR245409 (voxtalisib/XL765) blocks survival, adhesion and proliferation of primary chronic lymphocytic leukemia cells.
Thijssen R; Ter Burg J; van Bochove GG; de Rooij MF; Kuil A; Jansen MH; Kuijpers TW; Baars JW; Virone-Oddos A; Spaargaren M; Egile C; van Oers MH; Eldering E; Kersten MJ; Kater AP
Leukemia; 2016 Feb; 30(2):337-45. PubMed ID: 26338274
[TBL] [Abstract][Full Text] [Related]
20. IL4-STAT6 signaling induces CD20 in chronic lymphocytic leukemia and this axis is repressed by PI3Kδ inhibitor idelalisib.
Sandova V; Pavlasova GM; Seda V; Cerna KA; Sharma S; Palusova V; Brychtova Y; Pospisilova S; Fernandes SM; Panovska A; Doubek M; Davids MS; Brown JR; Mayer J; Mraz M
Haematologica; 2021 Nov; 106(11):2995-2999. PubMed ID: 34196167
[No Abstract] [Full Text] [Related]
[Next] [New Search]